Literature DB >> 12574430

Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion.

Minoru Narita1, Keisuke Mizuo, Hirokazu Mizoguchi, Mamoru Sakata, Michiko Narita, Leon F Tseng, Tsutomu Suzuki.   

Abstract

The aim of the present study was to investigate the role of dopamine D(3) receptors in the rewarding effect and hyperlocomotion induced by a prototypical mu-opioid receptor agonist morphine using dopamine D(3) receptor knock-out mice. The mu-opioid receptor in the brain determined by the [tylosil-3,5-(3)H(N)]-[D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin binding assay was not significantly changed by a deletion of the dopamine D(3) receptor gene. Furthermore, we found that no significant differences in G-protein activation by morphine in the limbic forebrain and lower midbrain were noted between the two genotypes. These results suggest that the function of the mu-opioid receptor itself was not affected by a deletion of the dopamine D(3) receptor gene. To ascertain the morphine-induced rewarding effect in both genotypes, the conditioned place preference paradigm was performed. Deletion of the dopamine D(3) receptor gene resulted in a remarkable enhancement of the morphine-induced rewarding effect. Furthermore, knock-out mice with deletions of the dopamine D(3) receptor revealed a dramatic potentiation of morphine-induced hyperlocomotion. Under these conditions, a loss of the dopamine D(3) receptor gene had no effect on the basal levels of dopamine and the increased dopamine turnover by morphine in the limbic forebrain. These findings provide further evidence that dopamine D(3) receptor contributes to the postsynaptically negative modulation of the mesolimbic dopaminergic pathway that is associated with the rewarding effect and hyperlocomotion through the stimulation of mu-opioid receptors induced by morphine in the mouse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574430      PMCID: PMC6741920     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  41 in total

1.  Up-regulation of the G(q/11alpha) protein and protein kinase C during the development of sensitization to morphine-induced hyperlocomotion.

Authors:  M Narita; K Mizuo; M Shibasaki; M Narita; T Suzuki
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

Review 2.  Regulations of opioid dependence by opioid receptor types.

Authors:  M Narita; M Funada; T Suzuki
Journal:  Pharmacol Ther       Date:  2001-01       Impact factor: 12.310

Review 3.  Drugs of abuse: anatomy, pharmacology and function of reward pathways.

Authors:  G F Koob
Journal:  Trends Pharmacol Sci       Date:  1992-05       Impact factor: 14.819

4.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

5.  Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats.

Authors:  R Maldonado; V Daugé; J Feger; B P Roques
Journal:  Neuropharmacology       Date:  1990-03       Impact factor: 5.250

6.  Dopamine D3 receptors expressed by all mesencephalic dopamine neurons.

Authors:  J Diaz; C Pilon; B Le Foll; C Gros; A Triller; J C Schwartz; P Sokoloff
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

7.  Intensification of the development of ethanol dependence in mice lacking dopamine D(3) receptor.

Authors:  Minoru Narita; Miho Soma; Hiroko Tamaki; Michiko Narita; Tsutomu Suzuki
Journal:  Neurosci Lett       Date:  2002-05-17       Impact factor: 3.046

8.  Drug interactions in the reinforcing effects of over-the-counter cough syrups.

Authors:  T Suzuki; Y Masukawa; M Misawa
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 9.  Brain dopamine and reward.

Authors:  R A Wise; P P Rompre
Journal:  Annu Rev Psychol       Date:  1989       Impact factor: 24.137

10.  Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.

Authors:  M L Bouthenet; E Souil; M P Martres; P Sokoloff; B Giros; J C Schwartz
Journal:  Brain Res       Date:  1991-11-15       Impact factor: 3.252

View more
  13 in total

1.  Molecular characterization of individual D3 dopamine receptor-expressing cells isolated from multiple brain regions of a novel mouse model.

Authors:  Ying Li; Eldo V Kuzhikandathil
Journal:  Brain Struct Funct       Date:  2012-01-29       Impact factor: 3.270

Review 2.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 3.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 4.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

5.  Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice.

Authors:  Jia Zhan; Chloe J Jordan; Guo-Hua Bi; Xiang-Hu He; Eliot L Gardner; Yan-Lin Wang; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2018-08-20       Impact factor: 5.250

6.  Brain stimulation and morphine reward deficits in dopamine D2 receptor-deficient mice.

Authors:  G I Elmer; J O Pieper; J Levy; M Rubinstein; M J Low; D K Grandy; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Brain Renin-Angiotensin System Blockade Attenuates Methamphetamine-Induced Hyperlocomotion and Neurotoxicity.

Authors:  Linhong Jiang; Ruiming Zhu; Qian Bu; Yan Li; Xue Shao; Hui Gu; Jueying Kong; Li Luo; Hailei Long; Wei Guo; Jingwei Tian; Yinglan Zhao; Xiaobo Cen
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

8.  The selective dopamine D3 receptor antagonist, SR 21502, reduces cue-induced reinstatement of heroin seeking and heroin conditioned place preference in rats.

Authors:  Ewa Galaj; Monica Manuszak; Sandra Babic; Subramaniam Ananthan; Robert Ranaldi
Journal:  Drug Alcohol Depend       Date:  2015-09-25       Impact factor: 4.492

Review 9.  Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.

Authors:  Zheng-Xiong Xi; Eliot L Gardner
Journal:  CNS Drug Rev       Date:  2007

10.  Maternal deprivation and handling modify the effect of the dopamine D3 receptor agonist, BP 897 on morphine-conditioned place preference in rats.

Authors:  Vincent Vazquez; Stéphanie Weiss; Bruno Giros; Marie-Pascale Martres; Valérie Daugé
Journal:  Psychopharmacology (Berl)       Date:  2007-05-10       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.